Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ETON): 12 pipeline candidates · 3 upcoming catalysts · ~7 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.2 months
D/E 2.19 · 15% dilution
Lead: Approved
12 candidates
3 upcoming, next in ~2447d
0 buys · 7 sells (180d)
A transparent, data-derived signal for Eton Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$865.3M
Cash
$19.7M
Quarterly Burn
$12.3M
Runway
7.2 mo
Revenue
$24.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| amglidia | Preclinical |
| betaine | Approved |
| desmoda | Approved |
| et-400 | BLA Filed |
| et-600 | Preclinical |
| et-700 | Preclinical |
| et-800 | Preclinical |
| hemangeol | Approved |
| nitisinone | Approved |
| sapablursen | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
111
Total value held
$287.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,988,178 | $49.1M |
| blackrock, inc. | 1,717,286 | $42.4M |
| geode capital management, llc | 577,666 | $14.3M |
| state street corp | 530,215 | $13.1M |
| morgan stanley | 477,957 | $11.8M |
| oberweis asset management inc/ | 439,300 | $10.8M |
| pillsbury lake capital llc | 364,954 | $9.0M |
| cannell capital llc | 341,985 | $8.4M |
| woodline partners lp | 341,398 | $8.4M |
| bnp paribas financial markets | 302,108 | $7.5M |
Showing top 10 of 111 institutional holders of Eton Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Eton Pharmaceuticals, Inc.'s pipeline?
Eton Pharmaceuticals, Inc. (ETON) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Eton Pharmaceuticals, Inc.'s lead drug candidate?
Eton Pharmaceuticals, Inc.'s most advanced tracked candidate is amglidia (Preclinical) for neonatal diabetes mellitus.
What is Eton Pharmaceuticals, Inc.'s next catalyst?
Eton Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ORFADIN" — expected February 28, 2033.
What is Eton Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Eton Pharmaceuticals, Inc. has approximately 7.2 months of cash runway.
What is Eton Pharmaceuticals, Inc.'s market capitalization?
Eton Pharmaceuticals, Inc.'s market capitalization is approximately $865.3M.
Get the full picture on Eton Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.